$5.24
Insights on Sight Sciences Inc
Revenue is down for the last 3 quarters, 23.47M → 18.75M (in $), with an average decrease of 10.5% per quarter
Netprofit is up for the last 4 quarters, -17.06M → -10.69M (in $), with an average increase of 16.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 69.4%
0.76%
Downside
Day's Volatility :3.7%
Upside
2.96%
80.15%
Downside
52 Weeks Volatility :90.71%
Upside
53.21%
Period | Sight Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 3.26% | -0.7% | 0.0% |
6 Months | 42.71% | 6.6% | 0.0% |
1 Year | -37.73% | 3.7% | -1.5% |
3 Years | -83.94% | 14.0% | -21.8% |
Market Capitalization | 259.2M |
Book Value | $2.45 |
Earnings Per Share (EPS) | -1.14 |
Wall Street Target Price | 5.63 |
Profit Margin | -68.53% |
Operating Margin TTM | -59.25% |
Return On Assets TTM | -18.85% |
Return On Equity TTM | -39.64% |
Revenue TTM | 81.1M |
Revenue Per Share TTM | 1.67 |
Quarterly Revenue Growth YOY | -8.7% |
Gross Profit TTM | 59.0M |
EBITDA | -56.7M |
Diluted Eps TTM | -1.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.97 |
EPS Estimate Next Year | -0.88 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.3 |
What analysts predicted
Upside of 7.44%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.5M | - |
Net Income | -14.3M | - |
Net Profit Margin | -189.77% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 23.3M | ↑ 210.07% |
Net Income | -25.9M | ↑ 81.03% |
Net Profit Margin | -110.8% | ↑ 78.97% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 27.6M | ↑ 18.38% |
Net Income | -34.7M | ↑ 34.11% |
Net Profit Margin | -125.52% | ↓ 14.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 49.0M | ↑ 77.12% |
Net Income | -63.0M | ↑ 81.48% |
Net Profit Margin | -128.61% | ↓ 3.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 71.3M | ↑ 45.7% |
Net Income | -86.2M | ↑ 36.98% |
Net Profit Margin | -120.9% | ↑ 7.71% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 81.1M | ↑ 13.63% |
Net Income | -55.5M | ↓ 35.59% |
Net Profit Margin | -68.53% | ↑ 52.37% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 18.7M | ↑ 8.4% |
Net Income | -22.2M | ↓ 6.77% |
Net Profit Margin | -119.02% | ↑ 19.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 20.5M | ↑ 9.99% |
Net Income | -16.9M | ↓ 23.94% |
Net Profit Margin | -82.3% | ↑ 36.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 8.37% |
Net Income | -17.1M | ↑ 0.95% |
Net Profit Margin | -90.67% | ↓ 8.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↑ 24.69% |
Net Income | -14.8M | ↓ 13.55% |
Net Profit Margin | -62.86% | ↑ 27.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.0M | ↓ 14.75% |
Net Income | -13.0M | ↓ 11.65% |
Net Profit Margin | -65.15% | ↓ 2.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 6.29% |
Net Income | -10.7M | ↓ 17.98% |
Net Profit Margin | -57.02% | ↑ 8.13% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 8.1M | - |
Total Liabilities | 37.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.7M | ↑ 279.8% |
Total Liabilities | 85.4M | ↑ 130.53% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 72.8M | ↑ 136.84% |
Total Liabilities | 161.7M | ↑ 89.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 280.2M | ↑ 284.84% |
Total Liabilities | 48.1M | ↓ 70.26% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 213.1M | ↓ 23.95% |
Total Liabilities | 53.0M | ↑ 10.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 166.7M | ↓ 21.79% |
Total Liabilities | 46.4M | ↓ 12.38% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 225.2M | ↓ 6.44% |
Total Liabilities | 52.3M | ↑ 6.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 213.1M | ↓ 5.4% |
Total Liabilities | 53.0M | ↑ 1.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 196.6M | ↓ 7.71% |
Total Liabilities | 50.3M | ↓ 5.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 185.3M | ↓ 5.77% |
Total Liabilities | 49.2M | ↓ 2.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 176.6M | ↓ 4.67% |
Total Liabilities | 49.6M | ↑ 0.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 166.7M | ↓ 5.66% |
Total Liabilities | 46.4M | ↓ 6.33% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.5M | - |
Investing Cash Flow | -570.0K | - |
Financing Cash Flow | 12.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.0M | ↑ 72.69% |
Investing Cash Flow | -672.0K | ↑ 17.89% |
Financing Cash Flow | 42.7M | ↑ 249.62% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.2M | ↑ 28.71% |
Investing Cash Flow | -953.0K | ↑ 41.82% |
Financing Cash Flow | 73.4M | ↑ 72.04% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -52.5M | ↑ 63.3% |
Investing Cash Flow | -813.0K | ↓ 14.69% |
Financing Cash Flow | 252.5M | ↑ 244.04% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.0M | ↑ 44.59% |
Investing Cash Flow | -970.0K | ↑ 19.31% |
Financing Cash Flow | 1.2M | ↓ 99.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.2M | ↑ 10.31% |
Investing Cash Flow | -272.0K | ↓ 20.47% |
Financing Cash Flow | 186.0K | ↑ 17.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.5M | ↓ 23.23% |
Investing Cash Flow | -129.0K | ↓ 52.57% |
Financing Cash Flow | 812.0K | ↑ 336.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.4M | ↑ 12.13% |
Investing Cash Flow | -126.0K | ↓ 2.33% |
Financing Cash Flow | -156.0K | ↓ 119.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.5M | ↓ 22.4% |
Investing Cash Flow | -97.0K | ↓ 23.02% |
Financing Cash Flow | 766.0K | ↓ 591.03% |
Sell
Neutral
Buy
Sight Sciences Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sight Sciences Inc | 14.23% | 42.71% | -37.73% | -83.94% | -83.94% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sight Sciences Inc | NA | NA | NA | -0.97 | -0.4 | -0.19 | NA | 2.45 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sight Sciences Inc | Buy | $259.2M | -83.94% | NA | -68.53% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
KCK Ltd
Bank of America Corp
UBS Group AG
Jackson Square Partners, LLC
Vanguard Group Inc
BlackRock Inc
Sight Sciences Inc’s price-to-earnings ratio stands at None
Read Moresight sciences, inc. is a medical devices company based out of menlo park, california, united states.
Organization | Sight Sciences Inc |
Employees | 214 |
CEO | Mr. Paul Badawi |
Industry | Healthcare |